Yahoo
Swiss - Delayed Quote CHF

Santhera Pharmaceuticals Holding AG (SANN.SW)

15.32 -0.28 (-1.79%)
At close: October 30 at 5:30:30 PM GMT+1
Chart Range Bar
Loading chart for SANN.SW
  • Previous Close 15.60
  • Open 15.58
  • Bid --
  • Ask --
  • Day's Range 15.12 - 15.58
  • 52 Week Range 10.06 - 18.84
  • Volume 51,276
  • Avg. Volume 77,305
  • Market Cap (intraday) 234.691M
  • Beta (5Y Monthly) -0.39
  • PE Ratio (TTM) --
  • EPS (TTM) -2.24
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 27.50

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

www.santhera.com

93

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

SANN.SW
21.59%
MSCI WORLD (^990100-USD-STRD)
9.06%

1-Year Return

SANN.SW
51.08%
MSCI WORLD (^990100-USD-STRD)
9.89%

3-Year Return

SANN.SW
32.99%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

SANN.SW
15.89%
MSCI WORLD (^990100-USD-STRD)
53.16%

Analyst Insights

View More

Analyst Price Targets

25.00
27.50 Average
15.32 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.46%

  • Return on Assets (ttm)

    -3.93%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    101.5M

  • Net Income Avi to Common (ttm)

    -31.93M

  • Diluted EPS (ttm)

    -2.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    41.77M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -21.16M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: